High-throughput methods for measuring heparanase activity and screening potential antimetastatic and anti-inflammatory agents.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Analytical Biochemistry

• Publication date

  2004-10-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.AB.2004.06.023PMID 15450817
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heparanase and Tumor Metastasis

  2004cited by this paper
• A multiwell format assay for heparanase.

  2003cited by this paper
• Regulation of heparanase gene expression by estrogen in breast cancer.

  2003cited by this paper
• Heparanase-1 expression is associated with the metastatic potential of breast cancer.

  2002cited by this paper
• Expression of heparanase in oral cancer cell lines and oral cancer tissues.

  2001cited by this paper
• Properties and function of heparanase in cancer metastasis and angiogenesis.

  2001cited by this paper
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

  1999cited by this paper
• Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.

  1999cited by this paper
• Comparison of methods of immobilization to enzyme-linked immunosorbent assay plates for the detection of sugar chains.

  1999cited by this paper
• Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis

  1999cited by this paper
• Human Heparanase

  1999cited by this paper
• Human platelet heparanase: purification, characterization and catalytic activity.

  1998cited by this paper
• Evidence that glypican is a receptor mediating β‐amyloid neurotoxicity in PC12 cells

  1998cited by this paper
• Time-resolved fluorometry: an overview of the labels and core technologies for drug screening applications

  1997cited by this paper
• A rapid quantitative assay for the detection of mammalian heparanase activity.

  1997cited by this paper
• Characterization of human recombinant interleukin 2 binding to heparin and heparan sulfate using an ELISA approach.

  1997cited by this paper
• Human prostate carcinoma cells produce extracellular heparanase.

  1997cited by this paper
• Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis

  1996cited by this paper
• Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Inhibition of tumor metastasis by heparanase inhibiting species of heparin.

  1994cited by this paper
• Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation.

  1992cited by this paper
• Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix.

  1992cited by this paper
• The role of proteoglycans in cell adhesion, migration and proliferation.

  1992cited by this paper
• Proteoglycans: structures and interactions.

  1991cited by this paper
• Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes.

  1991cited by this paper
• Heparanase activity in cultured endothelial cells

  1991cited by this paper
• Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix.

  1990cited by this paper
• Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins.

  1989cited by this paper
• High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons.

  1989cited by this paper
• Human mononuclear cells contain an endoglycosidase specific for heparan sulphate glycosaminoglycan demonstrable with the use of a specific solid-phase metabolically radiolabelled substrate.

  1989cited by this paper
• Inhibition of allergic encephalomyelitis in rats by treatment with sulfated polysaccharides.

  1988cited by this paper
• Heparanases and tumor metastasis

  1988cited by this paper
• Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour‐cell‐derived heparanases

  1987cited by this paper
• Europium as a label in time-resolved immunofluorometric assays.

  1984cited by this paper

• Chemical toolbox to interrogate Heparanase-1 activity.

  2024cites this paper
• Design Principle of Heparanase Inhibitors: A Combined In Vitro and In Silico Study.

  2024cites this paper
• Discovery and development of small-molecule heparanase inhibitors.

  2023cites this paper
• An Enzymatic Activity Assay for Heparanase That Is Useful for Evaluating Clinically Relevant Inhibitors and Studying Kinetics.

  2023cites this paper
• Glycosaminoglycan / gold nanocluster hybrid nanoparticles as a new sensing platform: Metastatic potential assessment of cancer cells.

  2020cites this paper
• A Cell-Based Renilla Luminescence Reporter Plasmid Assay for High-Throughput Screening to Identify Novel FDA-Approved Drug Inhibitors of HPV-16 Infection

  2020cites this paper
• Polymeric fluorescent heparin as one-step FRET substrate of human heparanase.

  2019cites this paper
• The Development of Assays for Heparanase Enzymatic Activity: Towards a Gold Standard

  2018cites this paper
• Cloning and bacterial expression systems for recombinant human heparanase production: Substrate specificity investigation by docking of a putative heparanase substrate

  2018cites this paper
• Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases.

  2016cites this paper
• Functional and structural characterization of a heparanase.

  2015cites this paper
• Fluoroscein‐5‐isothiocyanate (FITC)

  2015cites this paper
• Development of new methods for determining the heparanase enzymatic activity.

  2015cites this paper
• Development of both colorimetric and fluorescence heparinase activity assays using fondaparinux as substrate.

  2012cites this paper
• Synthesis of simple heparanase substrates.

  2011cites this paper
• Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening.

  2010cites this paper
• Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88.

  2008cites this paper
• Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis?

  2008cites this paper
• High-Performance Liquid Chromatographic/Mass Spectrometric Studies on the Susceptibility of Heparin Species to Cleavage by Heparanase

  2007cites this paper
• The Development of a Diagnostic Test for Heparanase Activity

  2007cites this paper
• High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase.

  2007cites this paper
• Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis.

  2006cites this paper
• An ELISA method for the detection and quantification of human heparanase.

  2006cites this paper
• Development of heparanase inhibitors for anti-cancer therapy.

  2006cites this paper
• High-throughput measurements of biochemical responses using the plate::vision multimode 96 minilens array reader.

  2006cites this paper
• High-Throughput Screening: Enabling and Influencing the Process of Drug Discovery

  2006cites this paper